From: Efficacy and safety of plasma exchange for Kawasaki disease with coronary artery dilatation
Patient | Gender | Age (months) | BW (kg) | Start of IVIG (day) | Treatment before PE | Dose of IVIG | Period of PSL (day) | Additional treatment of IVIG |
---|---|---|---|---|---|---|---|---|
1 | M | 7 | 7.5 | 6 | ASA, PSL, IVIG × 3 | 1 g/kg × 2, 2 g/kg × 1 | 11–30 | – |
2 | M | 29 | 13.8 | 4 | ASA, PSL, IVIG × 2 | 2 g/kg × 2 | 7.11 | – |
3 | M | 7 | 7.4 | 4 | ASA, PSL, IVIG × 2 | 1 g/kg × 2 | 6–8 | 1 g/kg × 2 (days 9 and 10), 2 g/kg × 2 (day 11) |
4 | M | 11 | 8.0 | 4 | ASA, IVIG × 2 | 2 g/kg × 2 | – | – |
5 | F | 3 | 4.5 | 5 | ASA, IVIG × 2 | 2 g/kg × 2 | 14–59 | 2 g/kg × 2 (days 14 and 18) |
6 | M | 36 | 13.3 | 4 | ASA, PSL, IVIG × 2 | 2 g/kg × 2 | 7,8 | 2 g/kg × 2 (day 13) |
7 | M | 53 | 14.0 | 4 | ASA, PSL, IVIG × 3 | 1 g/kg × 2, 2 g/kg × 1 | 6–8 | – |
8 | M | 17 | 10.2 | 4 | PSL, IVIG × 2 | 2 g/kg × 2 | 6–27 | 2 g/kg × 2 (day 14) |
9 | F | 12 | 11.9 | 21 | ASA, PSL, IVIG × 1 | 1 g/kg × 1 | 4, 10, 11, 14 | – |
10 | M | 63 | 17.8 | 5 | ASA, PSL, IVIG × 3 | 2 g/kg × 3 | 6, 8, 9 | 2 g/kg × 2 (days 10 and 20) |